- Indication
- Epilepsy
- RAG rating
- Amber initiation
- Document type
- Decision document
- Place
- Hertfordshire and West Essex ICB
- Output type
- Pharmacy / Prescribing
Zonsamide capsules
HERTFORDSHIRE AND WEST ESSEX AREA
PRESCRIBING COMMITTEE (HWE APC)
Zonisamide capsules for treating
epilepsy
AMBER INITIATION
Recommended for initiation by specialists, ongoing
prescribing in primary care, following stabilisation of therapy, and after an assessment
of tolerability and efficacy has been made by the specialists.
|
Name
generic:
|
Zonisamide
capsules
|
|
What
it is:
|
Anti-seizure
medicine
|
|
Indication:
|
Licensed
as monotherapy in the treatment of partial
seizures, with or without secondary generalisation, in adults with newly
diagnosed epilepsy and adjunctive therapy in the treatment of partial
seizures, with or without secondary generalisation, in adults, adolescents,
and children aged 6 years and above.
|
|
Date
decision last revised:
|
March
2025
|
|
NICE
|
NICE
NG217 recommended
|
HWE APC recommendation:
Zonisamide capsules are recommended for restricted use as an
option in children, young people and adults in line with NICE guidance NG217.
AMBER
INITIATION:
- At initiation, specialists must also counsel the patient on all aspects related to the safe and effective use of this medication.
- During treatment, periodic check-ups must be carried out according to standard clinical practice.
Further information:
for latest updates and more detailed information, including contra-indications,
cautions and special warnings; please refer to summary of product
characteristics (SPC).
- Version number
- 1.0
- Developed by
- HWE ICB Pharmacy Medicines Optimisation Team
- Approved by
- HWE ICB Area Prescribing Committee
- Date approved / updated
- March 2025
- Review date
- The recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.
- Superseded version
- N/A